Publikationen, an denen er mitarbeitet Iván Alejandro Ferraz Amaro (14)

2024

  1. Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis

    European Journal of Internal Medicine, Vol. 129, pp. 78-86

  2. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature

    Arthritis Research and Therapy, Vol. 26, Núm. 1

  3. Sex-specific impact of inflammation on traditional cardiovascular risk factors and atherosclerosis in axial spondyloarthritis. A multicentre study of 913 patients

    RMD open, Vol. 10, Núm. 2

2023

  1. Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 829-836

  2. Sex differences in cardiovascular and disease-related features in axial spondyloarthritis. A multicenter study of 912 patients

    Seminars in Arthritis and Rheumatism, Vol. 60

2022

  1. Cardiovascular and disease-related features associated with extra-articular manifestations in axial spondyloarthritis. A multicenter study of 888 patients

    Seminars in Arthritis and Rheumatism, Vol. 57

  2. Factors associated with atherosclerosis in radiographic and non-radiographic axial spondyloarthritis. A multicenter study on 838 patients

    Seminars in Arthritis and Rheumatism, Vol. 55

  3. Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis

    Frontiers in Immunology, Vol. 13

  4. Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients

    Therapeutic Advances in Musculoskeletal Disease, Vol. 14

  5. Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype

    Clinical and experimental rheumatology, Vol. 40, Núm. 4, pp. 727-733

2021

  1. Cranial and extracranial giant cell arteritis do not have different HLA-DRB1 and HLA-B association in Caucasian individuals

    Arthritis Research and Therapy

  2. Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis

    Therapeutic Advances in Musculoskeletal Disease, Vol. 13

  3. Subclinical atherosclerotic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study on 806 patients

    Seminars in Arthritis and Rheumatism, Vol. 51, Núm. 2, pp. 395-403

  4. Vaspin in atherosclerotic disease and cardiovascular risk in axial spondyloarthritis: a genetic and serological study

    Arthritis Research and Therapy, Vol. 23, Núm. 1